August 25, 2016 06:16 AM EDT

Novartis heralds a PhIII success for secondary progressive MS drug

Arsalan Arif

Founder

Novartis has scored a success for a Phase III study of BAF312 (siponimod), reducing the risk of crippling CNS damage in secondary progressive multiple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis heralds a PhIII success for secondary progressive MS drug

Arsalan Arif

Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis her­alds a PhI­II suc­cess for sec­ondary pro­gres­sive MS drug

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Novartis heralds a PhIII success for secondary progressive MS drug

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test